Back to Search Start Over

Population-based Laboratory Surveillance for AmpC β-Lactamase--producing Escherichia coli, Calgary.

Authors :
Pitout, Johann D. D.
Gregson, Daniel B.
Church, Deirdre L.
Laupland, Kevin B.
Source :
Emerging Infectious Diseases; Mar2007, Vol. 13 Issue 3, p443-448, 6p
Publication Year :
2007

Abstract

In the Calgary Health Region during 2000-2003, prospective, active, population-based laboratory surveillance for all cefoxitin-resistant Escherichia coli isolates was performed. Isolates were screened with an inhibitor-based disk test, and plasmid-mediated types were identified by multiplex PCR with sequencing. A total of 369 AmpC β-lactamase--producing E. coli isolates were identified; annual incidence rates were 1.7, 4.3, 11.2, and 15 per 100,000 residents for each year, respectively. AmpC β-lactamase-producing E. coli was 5x more likely to be isolated from female than male patients across all age groups except <1 year. Of these isolates, 83% were community onset, and urine was the principal site of isolation (90% of patients). PCR showed that 125 (34%) were positive for bla<subscript>cmy</subscript> genes; sequencing identified these enzymes to be CMY-2. In this large Canadian region, AmpC β-lactamase--producing E. coli is an emerging community pathogen that commonly causes urinary tract infections in older women. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
10806040
Volume :
13
Issue :
3
Database :
Complementary Index
Journal :
Emerging Infectious Diseases
Publication Type :
Academic Journal
Accession number :
24274658
Full Text :
https://doi.org/10.3201/eid1303.060447